Business
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. (" Theralase...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (\"PDCs\"), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated.Supported by current Good Manufacturing Practice (\"cGMP\") analysis conducted by an independent manufacturing and testing laboratory, Theralase® announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, RuvidarTM.Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase® stated, \"Theralase®'s ability to demonstrate such an extended shelf life of its lead PDC, RuvidarTM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of RuvidarTM to be an extremely stable small molecule that has the ability to maintain its potency and purity over 8 years without significant degradation. This will allow our clinical partners to procure and store our PDC technology over many years without loss of clinical performance, minimizing the requirement to dispose of / replace unused drug over time.\"Mr. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase® stated, \"Since 2015, Theralase® has utilized the services of an external, independent testing laboratory to conduct accelerated aging and real time stability studies in the storage of RuvidarTM, with the goal of validating product purity and hence efficacy over time. The recent stability report validates the storage of RuvidarTM over 8 years, providing Theralase® additional support that it's lead drug can be successfully manufactured and sterilized, then subsequently stored at clinical study sites around the globe for many years. This extended shelf life allows our future commercial partners to be confident in the ability to procure and store our lead drug without risk of degradation of clinical performance over time. This will...